Arzerra ofatumumab regulatory update

Genmab said FDA's Oncologic Drugs Advisory Committee will meet May 29 to discuss a BLA for Arzerra ofatumumab to treat patients with chronic lymphocytic leukemia (CLL) who have received prior therapy....